ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was upgraded by equities researchers at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Briefing.com reports. The firm currently has a $14.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $6.00. Raymond James’ price objective would suggest a potential upside of 322.96% from the stock’s previous close.
ProQR Therapeutics Stock Performance
PRQR stock opened at $3.31 on Tuesday. The stock’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $2.00. The company has a market cap of $270.36 million, a P/E ratio of -11.41 and a beta of 0.39. ProQR Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $4.62.
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.09. The company had revenue of $6.79 million for the quarter, compared to analysts’ expectations of $3.32 million. ProQR Therapeutics had a negative return on equity of 55.42% and a negative net margin of 140.17%. Equities analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.
Institutional Investors Weigh In On ProQR Therapeutics
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Featured Articles
- Five stocks we like better than ProQR Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 2 Stocks That Crushed Short Sellers With Impressive Gains
- 3 REITs to Buy and Hold for the Long Term
- 3 Global Semiconductor Stocks Set to Benefit From China’s EV Boom
- What Does a Stock Split Mean?
- Inflation Trades Gain Momentum: What Investors Should Watch
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.